Study S000846

Early Changes in Non-Invasive Hepatic and Metabolic Indices After Incretin-Based Therapy in Patients With Overweight or Obesity: Real-World Evidence From a Turkish Cohort

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT07701005
Acronym: GLP-NIT
Study type: OBSERVATIONAL
Status: COMPLETED
Enrollment: 154
Start: 2024-01-01
Primary completion: 2026-03-30
Lead sponsor: Goztepe Prof Dr Suleyman Yalcın City Hospital
Conditions: Steatosis of Liver; Metabolic Liver Injury; Obesity; Overweight; Insulin Resistance
Interventions: DRUG:Semaglutide; DRUG:Tirzepatide
Results posted: FALSE
Individual participant data sharing: NO

Registered primary outcomes

Change in Fibrosis-4 Index (FIB-4) [Baseline and follow-up (median 23.7 weeks; minimum 12 weeks)]
Change in AST-to-Platelet Ratio Index (APRI) [Baseline and follow-up (median 23.7 weeks; minimum 12 weeks)]
Change in Hepatic Steatosis Index (HSI) [Baseline and follow-up (median 23.7 weeks; minimum 12 weeks)]
Change in Triglyceride-Glucose (TyG) Index [Baseline and follow-up (median 23.7 weeks; minimum 12 weeks)]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.